Quick Answer
AVENUE THERAPEUTICS, INC. reported R&D Expense of $1.04 million for fiscal year 2025.
AVENUE THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.04M | -84.4% |
| 2024 | $6.64M | +8.4% |
| 2023 | $6.13M | +127.2% |
| 2022 | $2.70M | +799.3% |
| 2022 | $300.0K | -76.1% |
| 2021 | $1.25M | -56.2% |
| 2020 | $2.87M | -87.1% |
| 2019 | $22.19M | +25.4% |
| 2018 | $17.70M | +164.2% |
| 2017 | $6.70M | +403.2% |
| 2016 | $1.33M | +38.5% |
| 2015 | $961.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $177.0K | -92.4% | -7.8% |
| June 30, 2025 | $192.0K | -85.9% | -53.3% |
| March 31, 2025 | $411.0K | -82.8% | -82.3% |
| September 30, 2024 | $2.33M | +156.6% | +71.0% |
| June 30, 2024 | $1.36M | -55.0% | -43.1% |
| March 31, 2024 | $2.39M | +96.9% | +163.7% |
| September 30, 2023 | $907.0K | +367.5% | -70.0% |
| June 30, 2023 | $3.03M | +1904.6% | +149.1% |
- AVENUE THERAPEUTICS, INC. showed a decrease of -84.4% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, AVENUE THERAPEUTICS, INC.’s r&d expense has grown by 7.9% (from $961.0 thousand to $1.04 million).
- The most recent figure is from AVENUE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: